JP5792630B2 - Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 - Google Patents

Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Download PDF

Info

Publication number
JP5792630B2
JP5792630B2 JP2011546814A JP2011546814A JP5792630B2 JP 5792630 B2 JP5792630 B2 JP 5792630B2 JP 2011546814 A JP2011546814 A JP 2011546814A JP 2011546814 A JP2011546814 A JP 2011546814A JP 5792630 B2 JP5792630 B2 JP 5792630B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
sequence
peptide
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011546814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516140A (ja
JP2012516140A5 (enExample
Inventor
ダル ディガン フローレンス
ダル ディガン フローレンス
ジェイ．ニューマン マーク
ジェイ．ニューマン マーク
エル．アレキサンダー ジェフリー
エル．アレキサンダー ジェフリー
スコット　サウスウッド
サウスウッド スコット
Original Assignee
エピミューン，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピミューン，インコーポレイティド filed Critical エピミューン，インコーポレイティド
Publication of JP2012516140A publication Critical patent/JP2012516140A/ja
Publication of JP2012516140A5 publication Critical patent/JP2012516140A5/ja
Application granted granted Critical
Publication of JP5792630B2 publication Critical patent/JP5792630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011546814A 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Active JP5792630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14789209P 2009-01-28 2009-01-28
EP09151495 2009-01-28
EP09151495.0 2009-01-28
US61/147,892 2009-01-28
PCT/EP2010/050839 WO2010086294A2 (en) 2009-01-28 2010-01-26 Pan-dr binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2012516140A JP2012516140A (ja) 2012-07-19
JP2012516140A5 JP2012516140A5 (enExample) 2013-03-14
JP5792630B2 true JP5792630B2 (ja) 2015-10-14

Family

ID=42025833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546814A Active JP5792630B2 (ja) 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用

Country Status (4)

Country Link
US (2) US9249187B2 (enExample)
EP (1) EP2391635B1 (enExample)
JP (1) JP5792630B2 (enExample)
WO (1) WO2010086294A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
KR20160037196A (ko) 2013-07-31 2016-04-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 종양 연관된 탄수화물 항원을 표적으로 하는 암을 치료하고 예방하기 위한 조성물과 방법
AU2016306304A1 (en) 2015-08-07 2018-03-22 The University Of Birmingham Identification of class I MHC associated glycopertides as targets for cancer immunotherapy
CN109748952B (zh) * 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
EA202092808A1 (ru) * 2018-06-13 2021-08-24 Зе Скриппс Рисёрч Инститьют Вакцины на основе наночастиц с новыми структурными компонентами
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US20220383996A1 (en) 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
US20250186596A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants
WO2025231560A1 (en) * 2024-05-08 2025-11-13 The Governing Council Of The University Of Toronto Vaccine to mobilize b cells for therapy

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
NZ244102A (en) 1991-08-26 1996-12-20 Scripps Research Inst Peptides inducing cytotoxic t lymphocyte responses against hbv antigen and their use
WO1995003777A1 (en) 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
SG52492A1 (en) 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
ATE359089T1 (de) 1993-02-26 2007-05-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
JPH09502086A (ja) 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
JP3926839B2 (ja) * 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
AU6103896A (en) 1995-06-07 1996-12-30 Cytel Corporation Manufacture and purification of peptides
CA2242878C (en) * 1996-01-24 2010-06-22 Cytel Corporation Induction of immune response against desired determinants
BR9708161A (pt) 1996-03-11 1999-07-27 Epimmune Inc Peptídeos com aumentada afinidade de ligação para moléculas hla
DE69733352T2 (de) 1996-03-21 2006-04-27 Epimmune, Inc., San Diego Hla-a2.1 bindende peptide und deren verwendung
WO2004089973A2 (en) 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
JP2001509677A (ja) 1997-01-31 2001-07-24 エピミューン，インコーポレイティド Ｃｔｌを活性化するためのペプチドおよびペプチド担持抗原提示細胞
PT1447414E (pt) 1997-10-10 2007-07-18 Us Gov Health & Human Serv Péptidos antagonistas do antigénio carcinoembrionário ( cea ).
EP1064022A4 (en) 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
WO1999061916A1 (en) 1998-05-29 1999-12-02 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
EP1089757B1 (en) 1998-06-17 2009-04-22 IDM Pharma, Inc. Hla binding peptides and their uses
CA2345817C (en) 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
AU3215800A (en) 1999-01-27 2000-08-18 Epimmune, Inc. Identification of broadly reactive hla restricted t cell epitopes
JP2003535024A (ja) * 1999-06-29 2003-11-25 エピミューン インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの使用
WO2001021189A1 (en) 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
AU1075001A (en) 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001036452A2 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs of class i epitodes
EP1235848A4 (en) 1999-12-10 2005-02-09 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO CARCINOEMBRYONIC ANTIGEN USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU2087401A (en) 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
JP2003517310A (ja) 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
WO2001041788A1 (en) 1999-12-10 2001-06-14 Epimmune, Inc. INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
WO2001041741A1 (en) 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2394741A1 (en) 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2400215A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
JP2004508340A (ja) 2000-09-01 2004-03-18 エピミューン　インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
EP1343819A4 (en) 2000-09-01 2005-03-23 Epimmune Inc HLA-A2.1 BINDING SPEPTIDES AND THEIR USE
WO2002020035A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
KR20030055261A (ko) 2000-09-08 2003-07-02 에피뮨 인코포레이티드 펩티드 및 핵산 조성물을 이용한 ｂ형 간염 바이러스에대한 세포 면역 반응의 유도
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
EP1495322A4 (en) 2002-04-05 2006-09-06 Epimmune Inc HETEROKLITIC ANALOGUES AND ASSOCIATED METHODS
JP2006501827A (ja) 2002-10-03 2006-01-19 エピミューン インコーポレイテッド 最適化されたマルチエピトープ構築体及びその使用
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
ES2498371T3 (es) 2002-12-06 2014-09-24 Epimmune Inc. Antígenos de Plasmodium falciparum y procedimientos de uso
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2005089164A2 (en) 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CA2566506A1 (en) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2005120563A2 (en) 2004-06-04 2005-12-22 Pharmexa Inc. Induction of an immune response against streptococcus pneumoniae polysaccharides
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2007137586A2 (en) * 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
EP2069376A4 (en) 2006-07-21 2013-10-16 Pharmexa Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9910646B2 (en) 2015-12-26 2018-03-06 Intel Corporation Technologies for native code invocation using binary analysis

Also Published As

Publication number Publication date
JP2012516140A (ja) 2012-07-19
EP2391635B1 (en) 2017-04-26
US20110293646A1 (en) 2011-12-01
US9789181B2 (en) 2017-10-17
US9249187B2 (en) 2016-02-02
EP2391635A2 (en) 2011-12-07
US20160114035A1 (en) 2016-04-28
WO2010086294A3 (en) 2010-11-25
WO2010086294A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
US9789181B2 (en) PAN-DR binding polypeptides and uses thereof
US6413935B1 (en) Induction of immune response against desired determinants
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
EP2247306B1 (en) Immunogenic control of tumours and tumour cells
JP4063879B2 (ja) 所望の決定基に対する免疫応答の誘導
EP0907370B1 (en) Hla-a2.1 binding peptides and their uses
JPH03173830A (ja) ワクチン組成物
CA2386341A1 (en) Heteroclitic analogs and related methods
Abdel-Aal et al. Structure–activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates
JP2010535026A (ja) 多量体マルチエピトープインフルエンザワクチン
WO2020257317A1 (en) Rationally engineered carrier proteins for vaccines
CN113015541A (zh) 具有新氧化还原酶基序的免疫原性肽
McDonald et al. Synthesis of a self-adjuvanting MUC1 vaccine via diselenide-selenoester ligation-deselenization
JP2012523379A (ja) 免疫原性組成物およびその使用
US20050049197A1 (en) Induction of immune response against desired determinants
US20260001938A1 (en) Peptide used for immunotherapeutics
EP4138901A1 (en) Compositions and methods for inducing immune responses against class i fusion protein viruses
Gras-Masse Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations
WO2010027973A1 (en) Human papillomavirus / li-key hybrids and methods of use
US20150203830A1 (en) Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes
US20250332246A1 (en) Enhanced expression via autotransporters
CN100368436C (zh) 人绒毛膜促性腺激素重组多表位嵌合肽cp22抗原的分子设计及其制备方法
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
CN116528882A (zh) 用于免疫治疗剂的肽
Simerska et al. Liposaccharides in Peptide Vaccine Delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150806

R150 Certificate of patent or registration of utility model

Ref document number: 5792630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250